In lung cancer, ipilimumab has demonstrated poor efficacy in clinical studies.2, 5 Recently, a phase‐II trial investigating tremelimumab, an IgG2 antibody targeting CTLA‐4, in patients with relapsed malignant mesothelioma found no significant improvement to survival compared to placebo.38 The gene discussed is CTLA4; the disease is lung carcinoma.